Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-STAR: Early evolocumab plus statin + ezetimibe in acute coronary syndrome undergoing PCI
KCT0007908Phase 4Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Dec 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of evolocumab, ulinastatin, ezetimibe in acute coronary syndrome (ACS), atherosclerosis, coronary arteriosclerosis, hypercholesterolemia, sponsored by Daewoong Pharmaceutical. Started Dec 2022; status: completed.
02
Drugs
evolocumabulinastatinezetimibe
03
Conditions
acute coronary syndrome (ACS)atherosclerosiscoronary arteriosclerosishypercholesterolemia
Beyond the preview
Go deeper on KCT0007908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007908.